Intelligence · Clinical Pipeline
SUPERNUS PHARMACEUTICALS Pipeline
All ClinicalTrials.gov programs at SUPERNUS PHARMACEUTICALS — phase, modality, and trial IDs.
- Programs
- 8
Quick answer
SUPERNUS PHARMACEUTICALS has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
100mg SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder
1 trial -
APOKYN
SUPERNUS PHARMACEUTICALS, INC.
Parkinson's Disease
2 trials -
Botulinum Toxin Type B
SUPERNUS PHARMACEUTICALS, INC.
Cervical Dystonia
1 trial -
SPN-538
SUPERNUS PHARMACEUTICALS, INC.
Migraine Disorders
1 trial -
SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder (ADHD)
1 trial -
SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder
3 trials -
SPN-812 (600mg, QD)
SUPERNUS PHARMACEUTICALS, INC.
Healthy Lactating Women
1 trial -
ZULRESSO®
SUPERNUS PHARMACEUTICALS, INC.
Postpartum Depression
1 trial
Frequently asked questions
How many pipeline programs does SUPERNUS PHARMACEUTICALS have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs